EI
SONN

EAM Investors’s Sonnet BioTherapeutics SONN Stock Holding History

EAM Investors’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1
Closed -$981K – 334
2015
Q2 		$981K Buy
+1
New +$1.88M 0.11% 295

Other funds holding SONN

TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Intersect Capital San Ramon, California $331M AUM 6.79% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

EAM Investors's SONN Position: Q3 2015 in Review

EAM Investors sold out of Sonnet BioTherapeutics (SONN) in Q3 2015, closing a stake of 1 share — an estimated $981K sold.

EAM Investors first reported a position in SONN in Q2 2015 and held it in 1 quarter. The position peaked at $981K in Q2 2015. 1 fund tracked by Wall St. Rank holds SONN as of Q3 2015.

  • EAM Investors reported no remaining Sonnet BioTherapeutics position as of Q3 2015 after selling out during the quarter.
  • EAM Investors sold 1 Sonnet BioTherapeutics share in Q3 2015, an estimated $981K.
  • EAM Investors first reported a position in Sonnet BioTherapeutics in Q2 2015 and held it in 1 quarter.
  • EAM Investors's Sonnet BioTherapeutics position peaked at $981K in Q2 2015.
  • 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2015.

Based on EAM Investors's 13F filing for Q3 2015, filed 6 Nov 2015.